БҮЙРЕК ТРАНСПЛАНТАТЫН ҚАБЫЛДАМАУДЫ ДИАГНОСТИКАЛАУ ЖӘНЕ ЕМДЕУ: ӘДЕБИЕТТЕРГЕ ШОЛУ

Автор (лар): Абдугафаров С.А., Ассыкбаев М.Н., Даниярова Г.Д., Алтынова Ш.Х., Шайсултанова С.Т., Рахимжанова С.С., Пя Ю.В., Манатова А.М.

DOI: 10.34689/SH.2024.26.6.017

Ашу PDF түрінде жүктеу

Кіріспе. Бүйректі трансплантациялау созылмалы бүйрек жеткіліксіздігінің терминалды сатыларын емдеудің жалғыз радикалды әдісі болып табылады. Трансплантацияланған бүйректің жедел қабылдамау реакциясы реципиенттерде жиі кездесетін негізгі асқынулардың бірі болып саналады, ол тірі немесе қайтыс болған донордан кейін трансплантациядан бірнеше күн немесе айлар өткеннен кейін пайда болады және ағзаның бөгде тінге иммундық жауабы ретінде көрінеді. Мақсаты. Жедел және өте жедел бас тарту қабылдамау реакциясына баса назар аудара отырып, трансплантацияланған бүйректі қабылдамауды диагностикалау және емдеу бойынша қазіргі әдебиеттерді шолу және талдау. Іздестіру стратегиясы. PubMed және Google Scholar пайдаланып, «бүйректі трансплантациялау» және «қабылдамау» деген кілт сөздерді қамтитын барлық мақалалар табылды. Іздеу нәтижесінде 2014-2024 жылдар аралығында 50 нәтиже алынды. Нәтижелер. Трансплантацияланған бүйректің жедел қабылдамау реакциясы иммундық жүйенің трансплантацияланған органды бөгде ретінде танып, иммундық жауап тудырып, орган жасушаларының қабылданбауы мен жойылуына әкелуімен туындайды. Өте жедел бас тарту, қабылдамау алдын ала қалыптасқан антиденелермен туындайды, олар орган трансплантациясынан кейін алғашқы 72 сағат ішінде қабылдамау реакциясын қоздырады. Аурудың көріністері мен ағымы әр түрлі болғандықтан, бұл асқынудың салдары да әртүрлі болады, сондықтан ерте диагностика және емдеу өте маңызды. Қорытынды. Қауіпті болжау алгоритмдері болғанына қарамастан, бұл асқынулар, соның ішінде біздің елде де, алаңдатарлық тұрақтылықпен орын алады. Реципиенттерді амбулаторлық бақылаудың жетілмеген тәжірибелерімен және хаттамалық биопсиялардың болмауымен бірге бұл факторлар тіршілік деңгейіне тікелей әсер етеді.

Abdugafarov Sajtkarim Abdugapirovich –MD, Transplant surgeon National research oncology center, Kerey, Zhanibek Khandar str., house 3 Astana, Kazakhstan, 010000, e-mail: sait.surgeon@gmail.com ORCID ID: 0000-0002-8393-9966, num: +7(776) 994-01-20. Asykbayev Mels Nurseitovich - MD, Transplant surgeon National research oncology center, Kerey, Zhanibek Khandar str., house 3Astana, Kazakhstan, 010000, e-mail: dr.mels.assykbayev@mail.ru, ORCID ID: 0000 – 0003- 2386-0997,; num:+7(775)790-65-61. Daniyarova Gulnur Daniyarқyzy – Academic secretary, Corporate Fund “University Medical Center”, Astana, Kazakhstan, e-mail: daniyarova.g@umc.org.kz, ORCID ID: https://orcid.org/ 0000-0001-5876-7528, num: +7(705)596-50-60. Altynova Sholpan Hanapievna – MD, PhD, Professor, Director of Medical and Regulatory affairs Department, Corporate Fund “University Medical Center”, Astana, Kazakhstan, e-mail: Venera.Altynova@umc.org.kz, ORCID ID: 0009-0000-5592-0400, +7(702)999- 60-50. Shaisultanova Saule Talgatovna – MD, General Manager of Medical and Regulatory affairs Department, Corporate Fund “University Medical Center”, Astana, Kazakhstan, e-mail: shaisultanova.s@umc.org.kz. +7(778)737-90-70 Rakhimzhanova Saltanat Sagyndykovna – MD, Head of the Nephrology and Dialysis Program, Corporate Fund “University Medical Center”, Astana, Kazakhstan, e-mail: Saltanat.Rahimzhanova@umc.org.kz; num:+7(701)520-76-69 Pya Yuryi Vladimirovich – MD, PhD, Professor, Chairman of the Board of the Corporate Fund “University Medical Center”, Astana, Kazakhstan, e-mail:yuriy.pya@umc.org.kz, ORCID ID: 0000-0001-7249-0510, num:+7(7172) 69-25-41 Manatova Almira Manatkyzy – MD, PhD, leading specialist of science department, num:+87028802022, e-mail: m.almira@cancercenter.kz, https://orcid.org/0009-0007-6460-5606, LLP ‘National research oncology center’, Astana, Republic of Kazakhstan, num: +7(775)880-20-22.

1. Adams A.B., Goldstein J., Garrett C., Zhang R., Patzer R.E., Newell K.A., Turgeon N.A., Chami A.S., Guasch A., Kirk A.D., Pastan S.O., Pearson T.C., Larsen C.P. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. Am J Transplant. 2017 Nov. 17(11):2922-2936. doi: 10.1111/ajt.14353. Epub 2017 Jul 3. PMID: 28544101. PMCID: PMC5868947. 2. Adebiyi O.O., Gralla J., Klem P., Freed B., Davis S., Wiseman A.C., Cooper J.E. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients. Am J Transplant. 2016 Dec. 16(12):3458-3467. doi: 10.1111/ajt.13848. Epub 2016 Jun 15. PMID: 27140940. 3. Alquadan K.F., Womer K.L., Santos A.H., Zeng X., Koratala A. Not all inflammation in a renal allograft is rejection. Clin Case Rep. 2018 Sep 23. 6(11):2285-2286. doi: 10.1002/ccr3.1825. PMID: 30455940, PMCID: PMC6230630. 4. Becker J.U., Seron D., Rabant M., Roufosse C., Naesens M. Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials. Transpl Int. 2022 May 20. 35:10141. doi: 10.3389/ti.2022.10141. 5. Bloom R.D., Bromberg J.S., Poggio E.D., Bunnapradist S., Langone A.J., Sood P., Matas A.J., Mehta S., et al. Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol. 2017 Jul. 28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9. PMID: 28280140, PMCID: PMC5491290. 6. Bray R.A., Gebel H.M., Townsend R., Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018 Jul.18(7):1783-1789. doi: 10.1111/ajt.14721. Epub 2018 Apr 2. PMID: 29509295, PMCID: PMC6055714. 7. Chadban S.J., Ahn C., Axelrod D.A., Foster B., Kasiske B.L., Kher V., Kumar D., Oberbauer R., Pascual J., Pilmore H.L., et al. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr.104(4):708-714. doi: 10.1097/TP.0000000000003137. PMID: 32224812, PMCID: PMC7147399. 8. Chadban S.J., Bunnapradist S., Chapman J.R., Cohen D.J., Gritsch H.A., et al. Antithymocyte globulin in kidney transplantation: Clinical evidence. Clinical Transplantation. 2021. Т.35, №3. e14233. 9. Davis S., Gralla J., Klem P., Stites E., Wiseman A., Cooper J.E. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020. Apr.104(4):881-887. doi: 10.1097/TP.0000000000002913. PMID: 32224815. 10. Davis S., Cooper J.E. Acute antibody-mediated rejection in kidney transplant recipients. Transplant Rev (Orlando). 2017 Jan. 31(1):47-54. doi: 10.1016/j.trre.2016.10.004. Epub 2016 Oct 10. PMID: 28126347. 11. Davis S., Gralla J., Klem P., Stites E., Wiseman A., Cooper J.E. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020 Apr.104(4):881-887. doi: 10.1097/TP.0000000000002913. PMID: 32224815. 12. Gaber A.O., First M.R., Tesi R.J., Gaston R.S., Mendez R., Mulloy L.L., Light J.A., Gaber L.W., Squiers E., Taylor R.J., et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 2018 Jul 15.66(1):29-37. doi: 10.1097/00007890-199807150-00005. PMID: 9679818. 13. Ginevri F., Nocera A., Comoli P., Innocente A., Cioni M., Parodi A. et al. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant. 2014 12:3355–62. 10.1111/j.1600-6143.2012.04251.x 14. González-Almada A., Arreola-Guerra J.M., López-Sánchez J.A., Cuevas E., Vilatoba M., Contreras A.G., Morales-Buenrostro L.E., Alberu J., Uribe-Uribe N.O. Pretransplant angiotensin II type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients. Transpl Immunol. 2019 Jun. 54:1-8. doi: 10.1016/j.trim.2018.10.003. 15. Hart A., Smith J.M., Skeans M.A., Gustafson S.K., Stewart D.E., Cherikh W.S., Wainright J.L., Kucheryavaya A., Woodbury M., Snyder J.J., Kasiske B.L., Israni A.K. OPTN/SRTR 2015 Annual Data Report: Kidney. Am J Transplant. 2017 Jan. 17 Suppl 1(Suppl 1):21-116. doi: 10.1111/ajt.14124. PMID: 28052609. PMCID: PMC5527691. 16. Haas M., Loupy A., Lefaucheur C., Roufosse C., Glotz D., Seron D. et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018 18:293–307. 10.1111/ajt.14625 17. Halloran P.F., de Freitas D.G., Einecke G., Famulski K.S., Hidalgo L.G., Mengel M., Reeve J. Molecular diagnostics in kidney transplantation: Current practice and future possibilities. American Journal of Transplantation. 2019. Т. 19, № 5. С. 1136-1145. 18. Immenschuh S., Zilian E., Dämmrich M.E., Schwarz A., Gwinner W., Becker J.U., Blume C.A. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation. Transplantation. 2015 Jan. 99(1):56-62. doi: 10.1097/TP.0000000000000244. Erratum in: Transplantation. 2016 Mar. 100(3):e15. PMID: 25121474. 19. Krenzien F., Keshi E., Splith K., Griesel S., Kamali K., Sauer I.M., Feldbrügge L., Pratschke J., Leder A., Schmelzle M. Diagnostic Biomarkers to Diagnose Acute Allograft Rejection After Liver Transplantation: Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies. Front Immunol. 2019 Apr 11. 10:758. doi: 10.3389/fimmu.2019.00758. PMID: 31031758, PMCID: PMC6470197. 20. Loupy A., Haas, M. The Banff 2019 Kidney Meeting Report. American Journal of Transplantation. 2020. Т.20, №1. С. 14-24. 21. López Del Moral C., Wu K., Naik M., Osmanodja B., Akifova A., Lachmann N., Stauch D., Hergovits S., Choi M., Bachmann F., Halleck F., Schrezenmeier E., Schmidt D., Budde K. The natural history of de novo donor-specific HLA antibodies after kidney transplantation. Front Med (Lausanne). 2022 Sep 16. 9:943502. doi: 10.3389/fmed.2022.943502. PMID: 36186822. PMCID: PMC9523126. 22. Mayrdorfer M., Liefeldt L., Wu K., Rudolph B., Zhang Q., Friedersdorff F. et al. Exploring the complexity of death-censored kidney allograft failure. J Am Soc Nephrol. 2021. 32:1513–26. 10.1681/ASN.2020081215 23. Moroni G., Binda V., Quaglini S., Sacchi L., Raffiotta F., Cosa F., Montagnino G., Favi E., Messa P., Ponticelli C. Causes of late transplant failure in cyclosporine-treated kidney allograft recipients. Clin Exp Nephrol. 2019 Aug. 23(8):1076-1086. doi: 10.1007/s10157-019-01740-7. Epub 2019 Apr 23. PMID: 31016431. 24. Moreno Gonzales M.A., Gandhi M.J., Schinstock C.A., Moore N.A., Smith B.H., Braaten N.Y., Stegall M.D. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody. Transplantation. 2017 Jun. 101(6):1222-1227. doi: 10.1097/TP.0000000000001330. PMID: 27379560, PMCID: PMC4935916. 25. Malat G.E., Boyle S.M., Jindal R.M., Guy S., Xiao G., Harhay M.N., Lee D.H., Ranganna K.M., Anil Kumar M.S., Doyle A.M. Proteasome inhibitor-based therapy for antibody-mediated rejection. Am J Kidney Dis. 2019 Jan. 73(1):112-118. doi: 10.1053/j.ajkd.2018.02.352. Epub 2018 Apr 25. PMID: 29705074. 26. Moein M., Papa S., Ortiz N., Saidi R. Protocol Biopsy After Kidney Transplant: Clinical Application and Efficacy to Detect Allograft Rejection. Cureus. 2023 Feb 1;15(2):e34505. doi: 10.7759/cureus.34505. PMID: 36874304. PMCID: PMC9983784. 27. Naesens M., Kuypers D.R., De Vusser K., Evenepoel P., Claes K., Bammens B., et al. The histology of kidney transplant failure: a long-term follow-up study. Transplantation. (2014) 98:427–35. 10.1097/TP.0000000000000183 28. Lachmann N., Duerr M., Schönemann .C, Pruß A., Budde K., Waiser J. Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step. J Immunol Res. 2017.2017:6872046. doi: 10.1155/2017/6872046. Epub 2017 Jan 31. PMID: 28255562. PMCID: PMC5306998. 29. Orandi B.J., Chow E.H., Hsu A., Gupta N., Van Arendonk K.J., Garonzik-Wang J.M., Montgomery J.R., Wickliffe C., Lonze B.E., Bagnasco S.M, Alachkar N., Kraus E.S., Jackson A.M., Montgomery R.A., Segev D.L. Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant. 2015 Feb.15(2):489-98. doi: 10.1111/ajt.12982. Epub 2015 Jan 21. PMID: 25611786. PMCID: PMC4304875. 30. Orandi B.J. et al. Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA–Incompatible Kidney Transplantation. Transplantation. 2014. Т. 98. №. 8. С. 857-863. 31. Rampersad C., Balshaw R., Gibson I.W., Ho J., Shaw J., Karpinski M., et al. The negative impact of T cell–mediated rejection on renal allograft survival in the modern era. Am J Transplant. 2021. 22:761–71. 10.1111/ajt.16883. 32. Ravaioli M., Baldassare M., Vasuri F., Pasquinelli G., Laggetta M., Valente S., De Pace V., Neri F., Siniscalchi A., Zanfi C., Bertuzzo V.R., Caraceni P., Trerè D., Longobardi P., Pinna A.D. Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts. Ann Transplant. 2018 Jan 12;23:34-44. doi: 10.12659/aot.905406. PMID: 29326416. PMCID: PMC6248038. 33. Riella L.V., Safa K., Yagan J., Lee B., Azzi J., Najafian N., Abdi R., Milford E., Mah H., Gabardi S., Malek S., Tullius S.G., Magee C., Chandraker A. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation. 2014 Jun 27. 97(12):1247-52. doi: 10.1097/01.TP.0000442782.98131.7c. PMID: 24854670. 34. Roufosse C., Simmonds N., Clahsen-van Groningen M., Haas M., Henriksen K.J., Horsfield C, Loupy A., Mengel M., Perkowska-Ptasińska A., Rabant M., Racusen L.C., Solez K., Becker J.U. A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. Transplantation. 2018 Nov. 102(11):1795-1814. doi: 10.1097/TP.0000000000002366. 35. Sakamoto S., Iwasaki K., Tomosugi T., Niemann M., Spierings E., Miwa Y. et al. Analysis of T and B cell epitopes to predict the risk of de novo donor-specific antibody (DSA) production after kidney transplantation: a two-center retrospective cohort study. Front Immunol. 2020. 11:2000. 10.3389/fimmu.2020.02000. 36. Sawinski D., Trofe-Clark J., Leas B., Uhl S., Tuteja S., Kaczmarek J.L., French B., Umscheid C.A. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant. 2016 Jul. 16(7):2117-38. doi: 10.1111/ajt.13710. Epub 2016 Mar 15. PMID: 26990455. 37. Sautenet B., Blancho G., Büchler M., Morelon E., Toupance O., Barrou B., Ducloux D., Chatelet V., Moulin B., Freguin C. et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2016. 100: 391–399. 38. Seeman T., Vondrak K., Dusek J., Simankova N., Zieg J., Hacek J., Chadimova M., Sopko B., Fortova M. Differential diagnosis of acute allograft rejection and CMV-infection in renal transplantation by urinary cytology. Clin Lab. 2017 Jan 1. 63(1):111-114. doi: 10.7754/Clin.Lab.2016.160702. PMID: 28164508. 39. Sellarés J., de Freitas D.G., Mengel M., Reeve J., Einecke G., Sis B., Hidalgo L.G., Famulski K., Matas A., Halloran P.F. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 12: 388–399, 2012. 40. Tasaki M., Saito K., Nakagawa Y., Ikeda M., Imai N., Ito Y., Sudo M., Ikezumi Y., Yamada T., Hasegawa H., Kobayashi T., Miura K., Narita I., Takahashi K., Tomita Y. Bortezomib Eliminates Plasma Cells From a Renal Graft in Plasma Cell-Rich Acute Rejection. Transplant Proc. 2019 Jul-Aug. 51(6):1732-1738. doi: 10.1016/j.transproceed.2019.02.038. Epub 2019 Jul 10. PMID: 31301858. 41. Van Loon E., Senev A., Lerut E., Coemans M., Callemeyn J., Van Keer J.M. et al. Assessing the complex causes of kidney allograft loss. Transplantation. 2020. 104:2557–66. 10.1097/TP.0000000000003192. 42. Viglietti D., Gosset C., Loupy A., Deville L., Verine J., Zeevi A., Glotz D., Lefaucheur C. C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. Am J Transplant. 2016 May.16(5):1596-603. doi: 10.1111/ajt.13663. Epub 2016 Mar 3. PMID: 26693703. 43. Viglietti D., Loupy A., Vernerey D., Bentlejewski C., Gosset C., Aubert O., Duong van Huyen J.P., Jouven X., Legendre C., Glotz D., Zeevi A., Lefaucheur C. Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol. 2017 Feb. 28(2):702-715. doi: 10.1681/ASN.2016030368. Epub 2016 Aug 4. PMID: 27493255, PMCID: PMC5280026. 44. Vincenti F., Rostaing L., Grinyo J., Rice K., Steinberg S., Gaite L., Blancho G. Belatacept and long-term outcomes in kidney transplantation. American Journal of Transplantation. 2020. Т. 20, № 5. С. 1362-1370. 45. Webster A.C., Wu S., Tallapragada K., Park M.Y., Chapman J.R., Carr S.J. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev. 2017 Jul 20. 7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4. PMID: 28731207, PMCID: PMC6483358. 46. Wiebe C., Gibson I.W., Blydt-Hansen T.D., Pochinco D., Birk P.E., Ho J., Karpinski M., Goldberg A., Storsley L., Rush D.N., Nickerson P.W. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015 Nov. 15(11):2921-30. doi: 10.1111/ajt.13347. Epub 2015 Jun 10. PMID: 26096305. 47. Wiebe C., Gibson I.W., Blydt-Hansen T.D., Karpinski M., Ho J., Storsley L.J., Nickerson P.W. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. American Journal of Transplantation. 2019. Т. 19, № 4. С. 1104-1115. 48. Wehmeier C., Hönger G., Cun H., Amico P., Hirt-Minkowski P., Georgalis A., Hopfer H., Dickenmann M., Steiger J., Schaub S. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients. Am J Transplant. 2017 Aug. 17(8):2092-2102. doi: 10.1111/ajt.14247. Epub 2017 Mar 27. PMID: 28245084. 49. Wu K., Schmidt D., López Del Moral C., Osmanodja B., Lachmann N., Zhang Q. et al. Poor long-term renal allograft survival in patients with chronic antibody-mediated rejection, irrespective of treatment-a single center retrospective study. J Clin Med. 2021 11:199. 10.3390/jcm11010199. 50. Yamada C., Ramon D.S., Cascalho M., Sung R.S., Leichtman A.B., Samaniego M., Davenport R.D. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion. 2015 Apr. 55(4):727-35; quiz 726. doi: 10.1111/trf.12923. Epub 2014 Nov 11. PMID: 25385678, PMCID: PMC4911015.

Көрген адамдардың саны: 46

Түйенді сөздер: Бүйректі трансплантациялау, қабылдамау, донорға тән антиденелер.

Мақалалар санаты: Әдебиеттерге шолу

Библиографиялық сілтемелер

Абдугафаров С.А., Ассыкбаев М.Н., Даниярова Г.Д., Алтынова Ш.Х., Шайсултанова С.Т., Рахимжанова С.С., Пя Ю.В., Манатова А.М. Бүйрек трансплантатын қабылдамауды диагностикалау және емдеу: әдебиеттерге шолу // Ғылым және Денсаулық сақтау. 2024. Т.26 (6). Б. 142-151. doi 10.34689/SH.2024.26.6.017